All News

Found 541 articles

• Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

  5/9/2023

  Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the first quarter ending March 31, 2023, and highlighted recent progress.

• Mirati Therapeutics and Sarah Cannon Research Institute Announce Strategic, Community Site Focused Partnership to Increase Diversity in Oncology Clinical Studies

  5/8/2023

  Mirati Therapeutics, Inc.® and Sarah Cannon Research Institute announced a strategic partnership aimed at increasing diversity in clinical study recruitment practices.

• Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - May 5, 2023

  5/5/2023

  Mirati Therapeutics, Inc. today announced that the company granted equity awards to 2 new employees with a grant date of May 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company.

• Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs

  5/2/2023

  Incyte (Nasdaq:INCY) today reports 2023 first quarter financial results, and provides a status update on the Company’s clinical development portfolio.

• Mirati Therapeutics to Participate at the Bank of America Securities 2023 Health Care Conference

  4/27/2023

  Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Bank of America Securities 2023 Health Care Conference on May 11 at 10:00 a.m. P.T. / 1:00 p.m. E.T. Ben Hickey, chief commercial officer, will represent the company in a fireside chat at the conference.

• Journal of Clinical Oncology Publishes Rapid Communication Featuring Updated Clinical Data for Adagrasib as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors

  4/26/2023

  Mirati Therapeutics, Inc.® (NASDAQ: MRTX) announced today the Journal of Clinical Oncology published in a Rapid Communication data indicating adagrasib, a potent and selective KRASG12C inhibitor, is well tolerated and demonstrates meaningful clinical activity in patients with pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), and other solid tumors harboring a KRASG12C mutation.

• New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting

  4/26/2023

  Verastem Oncology, (Nasdaq: VSTM) today announced that an abstract highlighting updated interim results from Part A of the ongoing Phase 2, registration-directed RAMP 201 trial evaluating avutometinib (VS-6766) and defactinib in patients with low-grade serous ovarian cancer (LGSOC) has been selected for a presentation in a Poster Discussion Session at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2–6, 2023 in Chicago, IL.

• Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023

  4/25/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial results for the first quarter 2023 along with recent corporate updates on May 9, 2023.

• 

  Lilly Seeks First-Line KRAS Treatment with AACR Data Release

  4/19/2023

  Lilly investigators said they hoped to differentiate their Phase I candidate from the competitive KRAS space by making it the first to gain approval as a first-line treatment.

• Mirati To Present Research at the AACR Annual Congress for Two Potentially First-in-Class Clinical Stage Programs

  4/3/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a presentation demonstrating in preclinical models the ability of MRTX0902, a selective and potent SOS1 inhibitor, to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRASG12C inhibitor, or an epidermal growth factor receptor (EGFR)  inhibitor (e.g. osimertinib).

• Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update

  3/28/2023

  Aadi Bioscience, Inc. today provided a corporate update and announced financial results for the fourth quarter and full-year 2022.

• Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

  3/14/2023

  Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted recent progress.

• Mirati Therapeutics to Participate at the Barclays Global Healthcare Conference

  3/6/2023

  Mirati Therapeutics, Inc. will participate at the Barclays Global Healthcare Conference on March 14 at 6:00 a.m. P.T. / 9:00 a.m. E.T. 

• Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

  2/28/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial results for the fourth quarter and full year of 2022 along with recent corporate updates.

• BeiGene Reports Fourth Quarter and Full Year 2022 Financial Results

  2/27/2023

  BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today reported financial results for the fourth quarter and full year 2022, recent business highlights, and upcoming milestones.

• Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference

  2/21/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate at the 43rd Annual Cowen Health Care Conference on March 6 at 11:10 a.m. P.T. / 2:10 p.m. E.T. 

• Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023

  2/14/2023

  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results for the fourth quarter and full year of 2022 along with recent corporate updates on February 28, 2023.

• Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs

  2/7/2023

  Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs.

• Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - February 03, 2023

  2/3/2023

  Mirati Therapeutics, Inc., a clinical-stage targeted oncology company, announced that the company granted equity awards to 4 new employees with a grant date of February 1, 2023, as equity inducement awards outside of the company's 2022 Equity Incentive Plan and material to the employees' acceptance of employment with the company.

• KRAS Inhibitor Drug LUMAKRAS Sotorasib Krazati Adagrasib Market Forecast 2029

  2/3/2023

  Global KRAS Inhibitors Market, Drug Price, Sales, & Clinical Trials Insight 2029 Report Highlights: